Trial Profile
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Iodine-124; Iodine-131
- Indications Carcinoma; Thyroid cancer
- Focus Pharmacodynamics; Therapeutic Use
- 26 Jan 2024 Planned End Date changed from 12 Jan 2024 to 25 Jan 2025.
- 03 Feb 2023 Planned End Date changed from 12 Jan 2023 to 12 Jan 2024.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology